RedHill Biopharma Ltd. Commences a Pivotal Bioequivalence Trial with RHB-103 (An Oral Thin Film for the Treatment of Migraine); Subjects' Recruitment Completed; First Dose Administered; Results Expected within Months

Published: Apr 24, 2012

TEL AVIV, Israel--(BUSINESS WIRE)--RedHill Biopharma Ltd. (TASE: RDHL), an emerging Israeli biopharmaceutical company focusing primarily on development of late clinical-stage new formulations and combinations of existing drugs, has announced today the commencement of a pivotal bioequivalence clinical trial with RHB-103, an oral thin-film formulation of a leading triptan for the treatment of acute migraine. RedHill has completed screening and recruitment of all subjects for this clinical trial and announced subjects' first dosing on April 23rd, 2012.

Back to news